Using oncolytic viruses to enhance trafficking and infiltration of chimeric antigen receptor (CAR)-engineered Natural Killer cells to solid tumors for use as a novel combination therapy.

使用溶瘤病毒增强嵌合抗原受体（CAR）工程自然杀伤细胞向实体瘤的运输和浸润，用作新型联合疗法。

• 批准号: 458550
• 负责人: Portillo Ana
• 金额: $ 7.65万
• 依托单位: McMaster University
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-11-01 至 2024-11-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=458550&lang=en
• 关键词: Adoptive Cell Therapy; Breast Cancer; Cancer Immunotherapy; Chimeric Antigen Receptors; Immunology; Natural Killer Cells; Oncolytic Virotherapy; Solid Tumors

Breast cancer is the most common cancer affecting women worldwide. Triple negative breast cancer (TNBC) accounts for 12-15% of cases, and is the most aggressive form of breast cancer with the highest ability to spread. Currently, there are no approved tar

乳腺癌是影响全世界妇女的最常见癌症。三阴性乳腺癌（TNBC）占病例的12-15%，是最具侵袭性的乳腺癌形式，具有最高的扩散能力。目前，没有批准的焦油